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Neurologic Complications
in Transcatheter Aortic
Valve Replacement
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KEY POINTS
 Stroke remains a source of significant mortality, morbidity, and disability in the transcatheter
aortic valve replacement (TAVR) population.
 Acute periprocedural and remote strokes have differing mechanisms, hence mitigation
strategies.
 Although the use of cerebral embolic protection devices did not meet statistical significance for
preventing stroke, larger analyses suggest they have value in preventing stroke.
 Post-TAVR stroke prevention is controversial and limited by the bleeding profile of patients as
routine use of Factor Xa inhibitors and even dual antiplatelet therapy were a source of
significant morbidity in prospective studies.

INTRODUCTION
Transcatheter aortic valve replacement (TAVR)
has become the most commonly performed
treatment for symptomatic severe aortic stenosis
(AS) in patients across all surgical risk profiles.1
TAVR provides a life-saving and lifestyleimproving treatment for patients across all surgical risk profiles.2–5 Advancements in technology
and operator experience have resulted in diminishing rates of mortality, paravalvular aortic
insufficiency, postprocedure pacemaker implantation, and vascular complications.6
However, despite those advancements, the
rate of postprocedural stroke has remained relatively stable over time, with multiple studies
demonstrating a stroke rate in the 2% to 3%
range at 30 days post-TAVR in procedures performed between 2007 and 2018.7–10 These
TAVR stroke rates are lower than the comparator surgical aortic valve replacement.2,11

Stroke is one of the most feared, debilitating,
and costly complications of TAVR. Further
reducing stroke remains a central objective in the
treatment of aortic valve stenosis. In later discussion, the authors synthesize the state-of-the-art
and future of post-TAVR stroke and its prevention.

DEFINITIONS AND DISTINCTIONS
Standardized criteria for the definition of stroke
endpoints for TAVR clinical trials have been published by the Valve Academic Research Consortium. Diagnostic criteria involve “rapid onset
of a focal or global neurological deficit with at least
1 of the following: change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body,
dysphagia or aphasia, hemianopia, amaurosis
fugax, or other neurological signs or symptoms
consistent with stroke.”6 In addition, there should
be no readily identifiable nonstroke cause for the
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clinical presentation. Minor stroke is characterized
by a modified Rankin score less than 2, whereas
major stroke is characterized by a score 2.
Although the definition of stroke is relatively
clear, how stroke has been defined and studied
in TAVR is quite more complex.

True Incidence of Stroke Depends on the
Definition and Adjudication
Different TAVR trials have adjudicated the stroke
endpoint differently: some as disabling, others inclusive of those detected after careful examination, often by a neurologist, of subtle signs and
symptoms and that may yield no lifestyle-limiting
disabilities, and others detected with imaging,
such as MRI, sometimes in asymptomatic patients.
Analysis of the transcatheter valve therapy
(TVT) registry of about 100,000 TAVR procedures through the middle of 2017 shows stable
stroke rates (TVT registry represents sitereported stroke rates) despite improvements in
operator experience and device technology, of
about 2% to 2.5%.9 In comparison, trials (ie,
SENTINEL, DEFLECT III) whereby stroke is adjudicated based on careful neurologic assessment
(eg, National Institutes of Health Stroke Scale
before and after TAVR), the rates are in the
range of 9% to 15%; in trials for which new brain
MRI lesions are a principal endpoint (ie,
MISTRAL-C, CLEAN TAVI, SENTINEL), the rates
are much higher.10,12–14 Stroke rates in contemporary TAVR trials are shown in Fig. 1.
Importantly, nondisabling strokes should not
necessarily be considered benign or truly asymptomatic, as these may be associated with
steeper cognitive decline over time, an issue

that is of particular importance for the large
and growing number of younger low-risk patients that are undergoing TAVR.14

Relationship of Stroke to the Transcatheter
Aortic Valve Replacement Procedure Itself
Some strokes occur in the periprocedural
period, whereas other strokes occur remotely
from the procedure. It is critically important to
make these distinctions, as they have implications for mitigating the risk of these events. An
intraprocedural stroke has a different pathophysiological mechanism, incidence, and potential prevention strategy than a stroke remote
from the TAVR.

TIMING, MECHANISM, AND PREDICTORS
OF STROKE IN TRANSCATHETER AORTIC
VALVE REPLACEMENT PATIENTS
Timing
Post-TAVR strokes have been classified as acute
if occurring withing 24 hours, subacute if occurring from 1 day to 30 days post-TAVR, and late
if occurring after 30 days. Acute strokes occurring during or shortly after TAVR represent
most post-TAVR strokes. In cohort B of the landmark PARTNER trial, nearly two-thirds of the
strokes related to TAVR at 1 year occurred
within 30 days post-TAVR. In PARTNER, 85% of
the 30-day strokes occurred within the first
week, with the peak rate by day 2.15 Several
other studies have shown that stroke incidence
following TAVR has a peak in the immediate
period after the procedure (24–48 hours), with
some studies reporting half of the total events
occurring within 1 month.16,17 Among 3191

Fig. 1. Stroke rates vary across various contemporary TAVR trials, in part related to the definition of stroke used in
the trial protocol. *, refers to Kaplan Meier estimates.
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patients from the FRANCE-2 registry, strokes
were reported in 4%, with 48.5% of these events
occurring within the first 48 hours.17

Mechanism
Acute strokes are thought to be due to embolism of thrombus or fibrocalcific debris from
the valve site or because of atherothrombotic
emboli originating from ulcerative plaques in
the aortic arch or great cerebral vessels. Such
particles can be dislodged during wire/catheter/device manipulation across the aortic arch,
during attempts to traverse the aortic annulus
with wire and device, during balloon valvuloplasty, or valve deployment. Other potential
causes of stroke caused by TAVR include hypotension associated with rapid ventricular pacing
or hemodynamic instability during the procedure, especially in someone with preexisting cerebrovascular disease.6 Less than 5% of acute
strokes after TAVR
are
reported
as
hemorrhagic.18
Stroke that occurs after many days to weeks
or months after TAVR is presumably less related
to the TAVR procedure and more so to the patient’s underlying stroke risk factors. Many patients who have AS also have other
comorbidities that predispose them to ischemic
stroke, such as advanced age, hypertension, diabetes, atherosclerotic and calcific arterial disease of the aorta and cerebral vessels, and
atrial fibrillation.
Predictors/Risk Factors
It is important to establish reliable predictors of
stroke after TAVR so that periprocedural and
postprocedural care can be tailored on an individual basis. There are patient risk factors and
procedural risk factors. Table 1 summarizes
some of the reported risk factors, with more
detailed discussion later.
In a meta-analysis, female sex and underlying
chronic kidney disease (CKD) were baseline
characteristics that were associated with higher
risk of stroke post-TAVR.19 Female sex is associated with smaller aortic annuli and left ventricular outflow tract dimensions, and therefore,
higher mechanical interaction between the
native and aortic valve prosthesis. This finding
is supported by the PARTNER trial, which
demonstrated a higher rate of strokes (6.3% vs
2.8%) in patients with smaller aortic annuli and
valve area.15 CKD was also identified as a
patient-related risk factor (relative risk [RR]:
1.29; P 5 .03), thought to be related to its
inherent role in atherogenesis and/or the
absence of established guidelines regarding

Table 1
Reported stroke risk factors in TAVR,
categorized as patient- or procedure-related
Patient-Related

Procedure-Related

Female Gender
Older Age
Atrial fibrillation
Chronic kidney
disease
Smaller aortic
annular area
Degree of
aortic valve
calcification
Bicuspid aortic
valve
Carotid artery
disease
Peripheral arterial
disease
Prior Stroke

Valve dislodgement/
embolization
Non-transfemoral
TAVR Access

anticoagulation therapy for stroke prevention
in these patients.19
There was a nonstatistically significant signal
that balloon postdilation was associated with
higher risk of stroke. The strongest procedurerelated predictor of stroke occurring 1 to
30 days post-TAVR was new-onset atrial fibrillation (RR: 1.85; P 5 .005).
In a real-world sample of commercial TAVRs
performed in 2017, for which the ischemic stroke
rate was 2.4%, factors independently associated
with post-TAVR ischemic stroke included a history of carotid artery disease, peripheral artery
disease, atrial fibrillation or flutter, older age,
bicuspid aortic valve, and female sex.20,21
Atrial fibrillation has been consistently reported in studies investigating risk factors for
postprocedural stroke. New-onset atrial fibrillation has been identified as an independent predictor for 30-day stroke (odds ratio [OR] 2.27,
P 5 .018) and chronic atrial fibrillation as a major
contributor to late (>30 days) strokes occurring
in 3.3% of patients after a median follow-up of
12 months.16
Other potential risk factors for stroke after
TAVR include implantation of 2 valves, prior
stroke, coronary artery disease, valve dislodgement/embolization, degree of aortic valve calcification, and small index aortic valve area (cutoff
value of 0.4 cm2/m2).16,17,22,23
Presently, the balloon-expandable Sapien
valve (Edwards Life Sciences, Inc, Irvine, CA,
USA) and the self-expandable CoreValve Evolut
system (Medtronic, Inc, Minneapolis, MN, USA)
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are the 2 devices primarily used for the TAVR
procedure, with no strong evidence to suggest
statistically significant differences in stroke rates
between valve types.17,19,24 A meta-analysis of
transfemoral versus nontransfemoral (in this
analysis, transcarotid and transsubclavian approaches) TAVR revealed an increased risk of
stroke for the nontransfemoral route (OR 1.53;
confidence interval 1.05–2.22) when adjusting
for confounding factors.21 It is possible that the
risk adjustment does not fully account for the
higher stroke predisposition of patients that
require nontransfemoral TAVR. These nontransfemoral arterial alternative accesses were not
associated with an increased risk of adjusted
30-day death, bleeding, or vascular complication. Current data suggest no difference in
stroke rate with regard to transfemoral versus
transapical approach.19,24,25,26

IMPLICATIONS OF STROKE TO THE
PATIENT AND HEALTH CARE SYSTEM
Stroke has been shown to increase mortality in
TAVR patients, with a 30-day mortality of
16.7% compared with 3.7% in patients without
stroke.8 One meta-analysis revealed periprocedural stroke associated with a more than 6 times
greater risk of 30-day mortality.27,28
Silent or asymptomatic infarctions, as
assessed by brain MRI, have been associated
with steeper decline in cognitive function,
including impairments in memory performance,
psychomotor speed, and global cognitive function resulting in increased risk of dementia and
depression.29,30 Furthermore, stroke patients
who survive to hospital discharge are significantly less likely to go home following TAVR
(36.1% vs 78.9% in those without strokes,
P<.001).8
In an analysis of younger patients (age <65),
stroke was associated with significant financial
strains in 33%, an inability to return to work in
56%, and a decrease in participation in social activities in 79%.31 After a stroke, the additional
annual change in disability increases at a faster
rate than in those age-matched who did not
have stroke.32 Given the steep growth in TAVR
volume, the impact is further amplified with
wide-reaching consequences.
The financial burden of TAVR-related stroke
also cannot be understated, with an estimated
incremental cost of approximately $16,272 per
patient and an added length of stay of about
2.5 days for major stroke.33 In another analysis,
stroke is associated with a 33% increase in
average TAVR hospitalization cost (1$19,658),

a 6-day average increase in length of index hospitalization stay, and a 121% increase in nursing
home and intermediate care facility discharge.34

STROKE PREVENTION
As discussed, post-TAVR strokes can be acute
and often related to the procedure itself, or
subacute-late and more related to the inherent
stroke-predisposing milieu of the patient and
the transcatheter heart valve.
Efforts to reduce rates of acute stroke have
centered on meticulous intraprocedural technique, improved device technology, and intraprocedural cerebral embolic prevention device
use. Prevention of subacute and late stroke revolves around pharmacologic antiplatelet or
anticoagulant therapy as it relates to the transcatheter prosthesis and to the patient’s inherent
stroke risk factors, such as atrial fibrillation and
atherosclerotic vascular disease. Device therapy
with, for example, left atrial appendage closure
is also under investigation for the prevention of
subacute and late stroke after TAVR.

Intraprocedural Device Therapy
Cerebral embolic protection devices (CEPDs)
were developed to reduce the risk of strokes
and silent emboli by preventing procedural
debris from reaching cerebral vasculature.
Currently, the SENTINEL Cerebral Protection
System (Boston Scientific, Natick, MA, USA) is
the only Food and Drug Administration (FDA)approved device available for use in the United
States. It consists of 2 filters within a single 6F
delivery catheter percutaneously placed from
the right radial or brachial artery over a 0.014in guidewire.14 The filters are positioned in the
brachiocephalic and the left common carotid arteries before TAVR (Fig. 2), covering about 90%
of cerebral vascular circulation. The filters are
then withdrawn into the catheter and removed
after TAVR. The Sentinel device has been shown
to capture debris, including thrombus, valve tissue, calcified debris, artery wall, myocardium,
and foreign material, in 99% of TAVR patients,
which weighed heavily in the decision by the
FDA to approve the device. Fig. 3 shows debris
as captured during TAVR, and Fig. 4 shows fluoroscopic examples of in vivo Sentinel deployment during TAVR and illustrates some
techniques used to overcome more challenging
anatomies.
The SENTINEL trial randomized 363 patients
undergoing TAVR at 17 centers in the United
States and 2 centers in Germany to CEPD versus
no
protection.
The
device,
although
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Fig. 2. The Sentinel cerebral embolic
protection filter device.

manipulated and positioned in the great cerebral vessels, was shown to be safe: Sentinelrelated complications were 0.4%. The rate of
major adverse cardiac and cerebrovascular
events at 30 days was 7.3% and not statistically
different than that of the control group
(9.9%).14 Strokes at 30 days were 9.1% in control
subjects and 5.6% in patients with devices, also
statistically not significant (P 5 .25), in what
was an underpowered study for this endpoint.

Despite not achieving statistical significance,
the 72-hour data demonstrate 63% relative risk
reduction and 5.2% absolute risk reduction in
stroke.
The primary efficacy endpoint for this trial,
importantly, not stroke but rather new lesion volume on diffusion-weighted MRI in protected territories, was lower in the device arm (178.0 mm3)
as compared with the control arm (102.8 mm3)
but did not meet statistical significance

Fig. 3. Examples of debris retrieved
from the Sentinel device during
TAVR. (Courtesy of Tiberio Frisoli
MD.)
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Fig. 4. Fluoroscopic images during TAVR that serve as examples of Sentinel deployment. (A) Typical appearance
of Sentinel after deployment, with distal filter in left common carotid artery and proximal filter in brachiocephalic
artery. (B) Example of how, in a bovine arch anatomy, the guidewire can be passed directly into the left carotid
rather than into the ascending aorta, for delivery of the Sentinel. (C) Example of how, in bovine arch anatomy,
when one is unable or prefers not to pass the guidewire directly into the left common carotid artery, the device
can be flexed and turned around on itself in the distal ascending aorta to become coaxial with the left common
carotid to allow wiring. (D) After the operator does what is shown in panel (C), the rotation that was applied to
the device can be undone as it is pulled up into the left common carotid, after which the distal filter is pushed
forward.

(P 5 .33). Thus, the SENTINEL trial was a negative trial. However, after adjusting for valve
type and baseline T2/FLAIR lesion volume in a
post hoc analysis, there were significant differences in new lesion volumes favoring embolic
protection. There was also a correlation between lesion volume and neurocognitive decline
at 30 days.
In the MISTRAL-C randomized controlled
study, the Sentinel device had fewer new lesions
and a smaller total lesion volume (95 mm3 vs
197 mm3). Neurocognitive deterioration was
present in 4% of Sentinel CPS patients versus

27% without embolic protection.10 In the randomized controlled CLEAN-TAVI trial, the number of new lesions was lower in the filter group
compared with controls (4.00 vs 10.00), as was
the new lesion volume (242 mm3 vs
527 mm3).12 Meta-analysis data from the
SENTINEL, MISTRAL-C, and CLEAN-TAVI trials
showed a statistically significant reduction
(P 5 .017) in new brain lesions favoring Sentinel,
ultimately leading to FDA approval. Of note, the
Sentinel device does not provide complete cerebrovascular protection, as there is no filter in the
left vertebral artery territory.
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Real-world registry data have been favorable
for the Sentinel device. Stroke rates (disabling
and nondisabling) at 7 days after TAVR were
reduced by 70% (1.4% vs 4.6%; P 5 .03) at the
University of Ulm and by 78% (1.4% vs 6.3%;
P<.01) at Cedars-Sinai.35,36 When patients from
the SENTINEL trial were combined with the
CLEAN-TAVI and SENTINEL-Ulm studies in a patient level pooled analysis of 1306 patients with
propensity score matching, all stroke was significantly lower (1.88% vs 5.44%; P 5 .003; relative
risk reduction (RRR) 65%).37 A recently published
retrospective analysis of the Nationwide Inpatient Sample database from 2017, of 525 patients who underwent TAVR with CEPD and
1050 propensity score-matched patients who
underwent TAVR without CEPD, revealed a
lower ischemic stroke risk (1% vs 3.8%;
P 5 .003) and a higher cost of index hospitalization ($47,783 vs $44,578; P 5 .002), without an
increased risk of procedural complications.20
A major barrier to widespread Sentinel use
has been cost, as the Centers for Medicare and
Medicaid Services did not reimburse for its
use. As of October 2018, an add-on payment
went into effect for Sentinel use during TAVR.
Maximum new technology add-on payment for
a case involving Sentinel was $1400 for fiscal
year 2019. Cost is still a commonly cited barrier
for use of this device.
The TriGuard (Keystone) Embolic Deflection
Device is another form of cerebral embolic protection for use during TAVR. It is a nitinol mesh
filter positioned in the aortic arch across the
right brachiocephalic, left common carotid, and
left subclavian arteries and is designed to deflect
emboli away from cerebral circulation during
TAVR. The DEFLECT III trial randomized 85 subjects undergoing TAVR at 13 centers in Europe
and Israel from February 2014 to 2015 to TriGuard protection versus no protection. Results
from this prospective study showed that the device was safe to use, and patients who underwent TAVR with TriGuard protection had fewer
ischemic brain lesions, fewer neurologic deficits,
and improved cognitive function at discharge
and at 30 days compared with controls.13 However, results from the late-breaking REFLECT II
trial reported at the Transcatheter Cardiovascular Therapeutics Connect 2020 virtual conference showed that the TriGuard 3 failed to
demonstrate a statistically significant difference
in in-hospital and 30-day stroke compared with
controls.38
Only about 20% of all TAVR procedures in the
United States is performed with cerebral
embolic protection; in Germany over the past

3 years, only 3.8% of all TAVR cases were done
with cerebral protection.39
Many who do not use cerebral embolic protection regularly argue: it is a device that has
never been proven in a randomized trial to
reduce stroke; it does not protect all cerebral
vessels; cost is significant if not prohibitive.
Many who do use cerebral embolic protection
regularly tend to argue: the SENTINEL study was
underpowered; although it did not meet its primary endpoint, the findings from registries and
meta-analyses such as those discussed above
are compelling; for such a devastating complication as stroke, the use of a device that is proven
safe and effective at least at catching debris simply makes too much sense to be dismissed. A
common rhetorical question cited by proponents is: “If your mother were to undergo
TAVR, would you want cerebral embolic protection for her?”
At this time, a paucity of prospective randomized data showing a clinical stroke benefit,
coupled with a significant cost has led to a lack
of universal adoption of cerebral embolic protection in TAVR. The multicenter PROTECTEDTAVR trial aims to address this controversial
issue. It is an ongoing randomized controlled
trial scheduled for completion in 2022; the primary endpoint is clinically adjudicated stroke at
72 hours or discharge.

Post–Transcatheter Aortic Valve
Replacement Medical Therapy for the
Mitigation of Stroke Risk
Subclinical leaflet thrombosis, defined as hypoattenuated leaflet thickening (HALT) as detected
by high-resolution computed tomography (CT)
has been investigated as a potential risk factor
for post-TAVR stroke. The prevalence of HALT
among TAVR patients in PARTNER 3 was 10%
and 24% at 30 days and 1 year after TAVR,
respectively; spontaneous resolution of 30-day
HALT occurred in 54% of patients at 1 year.40
Although the individual endpoint of stroke was
not different between HALT and no HALT
groups, the pooled rates of stroke, transient
ischemic attack (TIA), and thromboembolic complications were higher in HALT than no HALT
groups (8.6 vs 1.6%; RRR 5.3). An analysis of
the RESOLVE and SAVORY registries revealed
no statistically significant difference in stroke
rates between those with (4.12 strokes per 100
person-years) or without (1.92 strokes per 100
person-years) CT-adjudicated reduced leaflet
motion.41 However, they did note that subclinical leaflet thrombosis was associated with
increased rates of TIAs (4.18 TIAs per 100
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person-years vs 0.60 TIAs per 100 person-years).
An analysis of the OCEAN-TAVI registry with CT
data out to 3 years after TAVR showed that early
HALT was present in 45 patients (9.3%) at a median time of 3 days.42 The investigators found
that the presence of early leaflet thrombosis
was not associated with in-hospital stroke.
Furthermore, the rates of ischemic and hemorrhagic stroke were similar between patients
with and without early leaflet thrombosis at a
mean follow-up of 1.8 years post-TAVR (0% vs
0.6%, P 5 .57; 0% vs 0.7%, P 5 .52, respectively).
Overall, the association between HALT and
stroke is still unclear.
Atrial fibrillation is common in patients undergoing TAVR and represents a major risk factor
for acute, subacute, and late post-TAVR
stroke.43,44 Reported incidences of stroke
among atrial fibrillation patients after TAVR
range from 3% to 12% in the first year after
TAVR, with a quarter of the strokes occurring
within the first 24 hours and half within
30 days.45,46 Guidelines recommend vitamin K
antagonist with or without antiplatelet therapy
for 3 to 6 months after TAVR in patients with
indication for anticoagulation, with the antiplatelet intended to prevent thromboembolism
before valve endothelialization.
In the POPular TAVI trial, cohort B, which
looked at patients with an already-established
indication for long-term anticoagulation, the
addition of 3 months of clopidogrel to oral anticoagulation (either vitamin K antagonist or
direct-acting oral anticoagulant) increased
bleeding (34.6% vs 21.7% for all bleeding;
16.7% vs 8.9% for major, life-threatening, or
disabling bleeding) without reducing stroke
(5.8% vs 5.1% for ischemic stroke).47 The
Kaplan-Meier curves for bleeding separate
almost immediately after TAVR and continue to
separate out to 90 days when clopidogrel was
discontinued, with most of the bleeding occurring within 1 week of TAVR.
The GALILEO trial, involving patients without
an established indication for oral anticoagulation
after TAVR, showed that rivaroxaban 10 mg
daily with aspirin was associated with more
bleeding and more death or thromboembolic
complications than aspirin with clopidogrel.48
Another analysis found that for patients with
hemorrhagic late strokes (>30 days postprocedure), the use of anticoagulation was more common than antiplatelet therapy (48.3% vs
27.2%).49
The aforementioned studies raise an important question: how do we adequately mitigate
the potential of late strokes in patients who

have undergone TAVR without putting them at
increased risk for bleeding? The ongoing prospective WATCH-TAVR randomized controlled
trial aims to address this dilemma by investigating the safety and effectiveness of left atrial
appendage occlusion with the WATCHMAN device in prevention of stroke and bleeding in patients with atrial fibrillation undergoing TAVR.
It is tentatively scheduled for completion in
November 2022.
In patients without an indication for long-term
anticoagulation, practice guidelines recommend
clopidogrel in addition to aspirin for the first 3 to
6 months after TAVR, for the purpose of mitigating the stent-mediated risk of thromboembolization before the valve has endothelialized.
This intensified dual antiplatelet regimen has
been shown in several series to result in major
or life-threatening bleeding in up to 15% of patients 1 year after TAVR.2,3,11 TAVR patients
are particularly prone to bleeding, as they tend
to be older with comorbidities that predispose
to bleeding, such as gastrointestinal angiodysplasia, and with postprocedure conditions, such
as transient thrombocytopenia, that further
augment this risk. Balancing stroke prevention
related to the transcatheter prosthesis and the
patient’s inherent stroke risk factors, with the
bleeding tendencies that many TAVR patients
possess, is a prominent focus of research.
Prospective studies, such as the ARTE trial,
showed a lower incidence of bleeding with
aspirin than with aspirin plus clopidogrel at
3 months.50 In cohort A of POPular, a comparison of aspirin with clopidogrel to aspirin alone,
for 3 months after TAVR, revealed that bleeding
was significantly higher (26.6% vs 15.1% for all
bleeding; 10.8% vs 5.1% for major, lifethreatening, or disabling bleeding), without a
benefit in ischemic outcomes (5.4 vs 5.1% for
ischemic stroke; 9.9 vs 9.7% for composite of
cardiovascular death, ischemic stroke, or
myocardial infarction), for the patients with a
dual antiplatelet regimen.51 The quality of these
pieces of data may call for a revision of postTAVR guideline recommendations.

SUMMARY
Stroke remains an issue for the TAVR procedure.
TAVR-related strokes are devastating to patients
and their families, and very costly for health care
systems. With the growth of TAVR volumes and
the expansion of TAVR indications to lower-risk,
younger, and often less symptomatic patients,
the mission to bring TAVR stroke rates down is
even more important. The predictors of stroke

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on December 16, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

Neurologic Complications in TAVR

in TAVR are not yet well defined, although older
age and female gender, carotid and peripheral
arterial disease, bicuspid aortic valve anatomy,
and atrial fibrillation are emerging as risk factors
across studies; the detection and appropriate
and prompt treatment of preexisting or newly
diagnosed atrial fibrillation represent a central
objective in the mitigation of stroke risk. For
acute stroke, there is an evolving body of evidence suggesting cerebral embolic protection
may mitigate the risk; more randomized
controlled data are forthcoming. For subacute
and late stroke, treating the intrinsic strokepredisposing milieu of patient and transcatheter
prosthesis requires careful individualized pharmacologic and nonpharmacologic therapy,
balancing risk of stroke with that of bleeding.

CLINICS CARE POINTS

 When counseling patients on risks and
benefits of TAVR, it is important to explain
that TAVR has a proven excellent safety and
efficacy profile, but that there is still a roughly
2% risk of clinically significant stroke.
 Patients should know that improving stroke
rates is a priority among those performing
and developing TAVR. Stroke prevention
strategies currently being utilized and studied
include devices placed during the TAVR
procedure into or near the arteries that
supply the brain, blood thinning medications,
early diagnosis and treatment of atrial
fibrillation, and further improved operator
experience and TAVR device technology.
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